Polyrizon

Polyrizon Financing Cash Flow

The Net Financing Cash Flow of Polyrizon (PLRZ) as of Oct 21, 2026 is 19.81 M USD. In the previous year, Net Financing Cash Flow was 3.67 M USD — a change of 440.19% (higher).

Financing Cash Flow

19.81 MUSD

YoY

440.19%

Last updated:

Net Financing Cash Flow of Polyrizon is 2025 19.81 M USD. Net Financing Cash Flow of Polyrizon was 2024 3.67 M USD. It decreases by 440.19% higher compared to the previous year.

The Polyrizon Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2020
89,000.00 USD
Jan 1, 2021
1.02 M USD
Jan 1, 2022
648,000.00 USD
Jan 1, 2023
505,000.00 USD
Jan 1, 2024
3.67 M USD
Jan 1, 2025
19.81 M USD
The Polyrizon Financing Cash Flow history
YEARFinancing Cash FlowYoY
19.81 MUSD+440.19%
3.67 MUSD+626.34%
505,000.00USD-22.07%
648,000.00USD-36.72%
1.02 MUSD+1,050.56%
89,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Polyrizon Stock analysis

What does Polyrizon do? Polyrizon Ltd develops medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity to block viruses and allergens. The company specializes in creating a biological mask using naturally occurring building blocks, focusing on both product development and commercialization. Medical specialists and researchers collaborate with Polyrizon Ltd to advance their intranasal solutions. The firm's primary revenue comes from the development and commercialization of its nasal spray hydrogel products. These products target healthcare providers and consumers seeking protection against viral and allergen exposure. By forming a shield containment barrier, Polyrizon Ltd offers a solution that complements existing health measures without requiring additional equipment. Polyrizon Ltd's business model centers on the creation of a unique nasal barrier technology. The company leverages its focus on intranasal delivery to address market needs for non-invasive protection. Its collaboration with medical specialists ensures that its products meet clinical standards and user requirements. Polyrizon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Polyrizon stock

Net Financing Cash Flow of Polyrizon is 19.81 M USD in 2025.

Net Financing Cash Flow of Polyrizon changed from 3.67 M USD to 19.81 M USD, representing a 440.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Polyrizon since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Polyrizon historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Polyrizon

All Key Metrics — Polyrizon